Key facts
- Imvax’s last known valuation is $237.4M (Jul 2020).
- It has raised $237.9M; the latest was Later Stage VC ($29.1M) in Jan 2025.
- Notable investors include Ben Franklin Technology Partners of Southeastern Pennsylvania, The Invus Group, Magnetar Capital, PEAK6 Strategic Capital, Reimagined Ventures — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Imvax
- ·The full record, as it builds
Funding rounds
No funding rounds for Imvax are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Imvax
Developer of patient-specific vaccines and immunotherapy strategies designed for the treatment of malignant gliomas and other cancers with unmet medical needs. The company's product is an autologous tumour cell vaccine that delivers a multi-pronged response against tumour cells by leveraging the patient's immune system as a defence mechanism, enabling physicians to find therapies and vaccines to treat brain tumours.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2015
- Employees
- 25
- Website
- imvax.com/
- Ownership
- Privately Held (backing)
Imvax doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Imvax shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Imvax in its N-PORT filings yet. We sweep new filings monthly.